1. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer. Issue 7 (27th June 2016) Authors: Duffy, A.G.; Makarova‐Rusher, O.V.; Ulahannan, S.V.; Rahma, O.E.; Fioravanti, S.; Walker, M.; Abdullah, S.; Raffeld, M.; Anderson, V.; Abi‐Jaoudeh, N.; Levy, E.; Wood, B.J.; Lee, S.; Tomita, Y.; Trepel, J.B.; Steinberg, S.M.; Revenko, A.S.; MacLeod, A.R.; Peer, C.J.; Figg, W.D. Journal: International journal of cancer Issue: Volume 139:Issue 7(2016:Oct. 01) Page Start: 1648 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗